Skip to main content
Clinical Trials/2024-513436-14-00
2024-513436-14-00
Recruiting
Phase III and phase IV (Integrated)

Evaluation of oxytocin treatment in children with autism and intellectual disability’, Multiple-dose Oxytocine - ASD and Intellectual Disability

UZ Leuven1 site in 1 country80 target enrollmentSeptember 20, 2024

Overview

Phase
Phase III and phase IV (Integrated)
Intervention
Not specified
Conditions
Not specified
Sponsor
UZ Leuven
Enrollment
80
Locations
1
Primary Endpoint
The Brief Observation of Social Communication Change (BOSCC) (clinician-rated)
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

To evaluate the efficacy of multiple-dose oxytocin treatment on core autism symptoms using standardized assessments in children with ASD and comorbid ID. Change from baseline after oxytocin administration on: -Behavioral measurements of core autism (social) symptoms -Cardio electrophysiological measurements of stress

Registry
euclinicaltrials.eu
Start Date
September 20, 2024
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product

Investigators

Sponsor
UZ Leuven
Responsible Party
Principal Investigator
Principal Investigator

Kaat Alaerts

Scientific

UZ Leuven

Eligibility Criteria

Inclusion Criteria

  • Children within an age-range of 4 to 13 years old with a clinical multidisciplinary diagnosis of ASD; only premenstrual girls will be included (girls with onset of menstruation during the course of the trial are allowed to continue the treatment).
  • Children must be enrolled in a special need school, more specific a class comprising children with an intellectual disability or meet intellectual disability criteria; a total IQ below 75 and an ABAS score below 70

Exclusion Criteria

  • Patient activelytakes anti-epileptic medication or has an active medical problem like cardiac pathology or serious liver, renal problems which influence the metabolism of oxytocin (IMP)
  • Patient has a known syndrome that interacts with the reproductive hormonal system (e.g. Prader-Willi or Angelman syndrome)
  • Significant hearing or vision impairments
  • Subjects who have had previous chronic treatment with oxytocin
  • Participation in another clinical trial with IMP
  • Known hypersensitivity to active substance or ingredients of the nasal spray

Outcomes

Primary Outcomes

The Brief Observation of Social Communication Change (BOSCC) (clinician-rated)

The Brief Observation of Social Communication Change (BOSCC) (clinician-rated)

The Autism Treatment Evaluation Checklist (ATEC) (parent (caregiver) and teacher-rated)

The Autism Treatment Evaluation Checklist (ATEC) (parent (caregiver) and teacher-rated)

Recordings of electrocardiography (ECG) for the assessment of heart rate variability (HRV) during rest

Recordings of electrocardiography (ECG) for the assessment of heart rate variability (HRV) during rest

Secondary Outcomes

  • The Repetitive Behavior Scale - Revised (RBS-R) (parent (caregiver) and teacher-rated)
  • The Adaptive Behavior Assessment System (ABAS-3) (parent (caregiver)-rated)
  • The Developmental Behaviour Checklist (DBC) (parent (caregiver)-rated)
  • The Perceived Stress Scale (PSS) (parent (caregiver)-rated)
  • The Child’s Sleep Habits Questionnaire Abbreviated (CSHQ-A) (parent (caregiver)-rated)

Study Sites (1)

Loading locations...

Similar Trials